CASI Pharma (NASDAQ: CASI) reported Q1 EPS of ($0.45), $0.12 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $8.35 million versus the consensus estimate of $9.1 million.

For earnings history and earnings-related data on CASI Pharma (CASI) click here.